All In Biotech

NDA 013684 · Baxter Hlthcare

Osmitrol 20% In Water In Plastic Container

Mannitol · Injection · Osmotic Diuretic

Last checked: Nov 20, 2026Latest source record: Aug 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1964

Jun 8, 1964

Approved uses

2

Original approval plus efficacy supplements

Registered trials

387

88 Phase 3, 30 recruiting

FAERS reports

4,991

4,752 serious, 1,439 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 26, 2025.

OSMITROL is indicated for: • The reduction of intracranial pressure and treatment of cerebral edema; • The reduction of elevated intraocular pressure. OSMITROL is an osmotic diuretic, indicated for the reduction of: • intracranial pressure and treatment of cerebral edema. ( 1 ) • elevated intraocular pressure. ( 1 )

Mechanism: Mannitol, when administered intravenously, exerts its osmotic diuretic effect as a solute of relatively small molecular size being largely confined to the extracellular space. Mannitol hinders tubular reabsorption of water and enhances excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate. This increase in extracellular osmolarity affected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 15, 2018 Supplement 104 · Efficacy LetterLabel
  • Jun 8, 1964 Original approval · Type 5 - New Formulation or New Manufacturer
8 products under this application
  • OSMITROL 20% IN WATER IN PLASTIC CONTAINER · MANNITOL 20GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • OSMITROL 5% IN WATER IN PLASTIC CONTAINER · MANNITOL 5GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • OSMITROL 20% IN WATER · MANNITOL 20GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • OSMITROL 5% IN WATER · MANNITOL 5GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • OSMITROL 15% IN WATER IN PLASTIC CONTAINER · MANNITOL 15GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • OSMITROL 10% IN WATER IN PLASTIC CONTAINER · MANNITOL 10GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • OSMITROL 15% IN WATER · MANNITOL 15GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • OSMITROL 10% IN WATER · MANNITOL 10GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Mannitol" as an intervention, any sponsor and status, largest first.

All 387 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain623
  • renal failure592
  • anxiety505
  • injury495
  • drug ineffective488
  • stress478
  • unevaluable event470
  • fear430
  • death428
  • off label use400
  • renal impairment394
  • emotional distress386

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004116
200580
200690
200759
200887
200973
2010105
2011578
2012255
2013106
2014181
2015126
2016228
2017259
2018218
2019190
2020226
2021307
2022379
2023394
2024395
2025318
2026220

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,010 on PubMed

Sponsor: Baxter Hlthcare · Also marketed as Osmitrol 5% In Water In Plastic Container, Osmitrol 20% In Water, Osmitrol 5% In Water, Osmitrol 15% In Water In Plastic Container, Osmitrol 10% In Water In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.